IN8bio Statistics

Total Valuation

IN8bio has a market cap or net worth of $7.72 million. The enterprise value is $268,187.

Market Cap	7.72M
Enterprise Value	268,187

Important Dates

The next estimated earnings date is Thursday, August 7, 2025, after market close.

Earnings Date	Aug 7, 2025
Ex-Dividend Date	n/a

Share Statistics

IN8bio has 3.44 million shares outstanding. The number of shares has increased by 84.32% in one year.

Current Share Class	3.44M
Shares Outstanding	3.44M
Shares Change (YoY)	+84.32%
Shares Change (QoQ)	+8.25%
Owned by Insiders (%)	5.08%
Owned by Institutions (%)	13.64%
Float	2.93M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	0.46
P/TBV Ratio	0.57
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 4.30, with a Debt / Equity ratio of 0.31.

Current Ratio	4.30
Quick Ratio	4.02
Debt / Equity	0.31
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -174.66% and return on invested capital (ROIC) is -80.38%.

Return on Equity (ROE)	-174.66%
Return on Assets (ROA)	-73.25%
Return on Invested Capital (ROIC)	-80.38%
Return on Capital Employed (ROCE)	-157.37%
Revenue Per Employee	n/a
Profits Per Employee	-$1.52M
Employee Count	18
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -94.81% in the last 52 weeks. The beta is 0.18, so IN8bio's price volatility has been lower than the market average.

Beta (5Y)	0.18
52-Week Price Change	-94.81%
50-Day Moving Average	4.40
200-Day Moving Average	7.64
Relative Strength Index (RSI)	26.77
Average Volume (20 Days)	385,105

Short Selling Information

The latest short interest is 3.02 million, so 87.56% of the outstanding shares have been sold short.

Short Interest	3.02M
Short Previous Month	1.24M
Short % of Shares Out	87.56%
Short % of Float	n/a
Short Ratio (days to cover)	0.53

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-26.61M
Pretax Income	-31.96M
Net Income	-27.43M
EBITDA	-24.73M
EBIT	-26.61M
Earnings Per Share (EPS)	-$13.03

Full Income Statement

Balance Sheet

The company has $11.89 million in cash and $4.27 million in debt, giving a net cash position of $7.62 million or $2.21 per share.

Cash & Cash Equivalents	11.89M
Total Debt	4.27M
Net Cash	7.62M
Net Cash Per Share	$2.21
Equity (Book Value)	13.88M
Book Value Per Share	5.12
Working Capital	9.77M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$19.35 million and capital expenditures -$116,000, giving a free cash flow of -$19.47 million.

Operating Cash Flow	-19.35M
Capital Expenditures	-116,000
Free Cash Flow	-19.47M
FCF Per Share	-$5.65

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

IN8bio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-84.32%
Shareholder Yield	-84.32%
Earnings Yield	-347.85%
FCF Yield	-246.92%

Analyst Forecast

The average price target for IN8bio is $3.60, which is 60.71% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$3.60
Price Target Difference	60.71%
Analyst Consensus	Strong Buy
Analyst Count	2
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on June 6, 2025. It was a reverse split with a ratio of 0.0333333:1.

Last Split Date	Jun 6, 2025
Split Type	Reverse
Split Ratio	0.0333333:1

Scores

Altman Z-Score	n/a
Piotroski F-Score	2